KPTI · Karyopharm Therapeutics Inc. · Debt
$0.48
-0.04 (-6.84%)
At close · Oct 26
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$11.74M
Shares
22.68M
Volume · Oct 26
1.37M
Avg daily vol (3M)
1.94M
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 1,068,000 | 10-Q filed 2026-08-13 |
| Current portion of secured debt | 2026-06-30 | USD 40,307,000 | 10-Q filed 2026-08-13 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 5,183,000 | 10-Q filed 2026-08-13 |
| Noncurrent secured debt | 2026-06-30 | USD 85,047,000 | 10-Q filed 2026-08-13 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
1503802
CUSIP
48576U205
13F (30d)
10 filings
10 filers
Visit website
Investor relations